한글목차

유럽의 핵산 치료제 CDMO 시장 규모는 2023년 12억 7,000만 달러에 달했습니다. 이 시장은 2033년에는 38억 8,000만 달러에 달할 것으로 예상되며, 예측 기간인 2023-2033년 동안 11.80%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예측됩니다. 핵산 치료제 CDMO 시장은 만성질환 및 유전성 질환 치료에 대한 핵산 치료제 수요 증가, 위탁개발생산기관(CDMO)의 제조 공정 발전, 핵산 치료제 FDA 승인 급증, CDMO의 생산능력 확대 투자 증가 등 다양한 요인으로 인해 성장하고 있습니다.

유럽의 핵산 치료제 위탁개발 및 생산(CDMO) 시장은 괄목할 만한 성장세를 보이고 있습니다. 이러한 시장 성장의 배경에는 이 지역에서 유행하는 만성 및 유전성 질환을 치료하기 위한 핵산 기반 치료제에 대한 수요가 증가하고 있기 때문입니다. 또한 CDMO를 통한 제조 공정의 발전으로 핵산 치료제의 생산 효율성과 확장성이 향상되고 있습니다. 또한, 이 지역에서는 이러한 치료제에 대한 FDA 승인이 증가하고 있으며, 이는 수용과 채택이 확대되고 있음을 보여줍니다. 또한, 유럽 전역에서 CDMO 제조 시설 확장에 대한 투자가 증가하고 있어 시장 성장을 더욱 촉진하고 있습니다. 이러한 역동적인 상황은 이 지역의 혁신과 의료 발전에 대한 노력을 강조하며, 유럽을 세계 핵산 치료제 CDMO 시장의 주요 진입 국가로 자리매김하고 있습니다.

이 보고서는 유럽의 핵산 치료제 CDMO 시장에 대해 조사했으며, 시장 개요와 함께 화학 합성 방법별, 국가별 동향, 시장 진출기업 프로파일 등을 정리하여 전해드립니다.

목차

주요 요약

조사 범위

제1장 시장

• 시장 전망
• 업계 전망
• COVID-19가 핵산 치료제 CDMO에 미치는 영향
• 현재의 핵산 치료용 CDMO 상황
• 치료제에서 핵산의 중요한 용도
• 치료용으로 합성되는 핵산 유형
• 비즈니스 역학

제2장 핵산 치료제 CDMO 시장(지역별)

• 유럽의 핵산 치료제 CDMO 시장
  • 주요 조사 결과
  • 시장 역학
  • 시장 규모와 예측

제3장 시장 - 경쟁 벤치마킹과 기업 개요

• 경쟁 벤치마킹
  • 주요 전략과 전개
  • 시장 점유율 분석
  • 주요 기업 비주얼 그래픽스
• 기업 개요
  • AGC Biologics
  • BACHEM
  • Eurofins Scientific
  • LGC Science Group Holdings Limited
  • Merck KGaA

영문목차

The Europe Nucleic Acid Therapeutics CDMO Market Expected to Reach $3.88 Billion by 2033

Introduction to Europe Nucleic Acid Therapeutics CDMO Market

The Europe nucleic acid therapeutics CDMO market was valued at $1.27 billion in 2023 and is expected to reach $3.88 billion by 2033, growing at a CAGR of 11.80% during the forecast period 2023-2033. The nucleic acid therapeutics CDMO market is experiencing growth due to various factors, these include increasing demand for nucleic acid therapeutics in treating chronic and genetic illnesses, advancements in manufacturing processes by Contract Development and Manufacturing Organizations (CDMOs), a surge in FDA approvals for such therapeutics, and growing investments in expanding CDMO manufacturing capacities.

Market Introduction

The Europe nucleic acid therapeutics Contract Development and Manufacturing Organization (CDMO) market is witnessing significant growth. This expansion is driven by a rising demand for nucleic acid-based treatments to address chronic and genetic diseases prevalent in the region. Additionally, advancements in manufacturing processes by CDMOs are enhancing the production efficiency and scalability of nucleic acid therapeutics. The region has also seen an uptick in FDA approvals for these therapies, indicating growing acceptance and adoption. Moreover, increased investments in expanding CDMO manufacturing facilities across Europe are further fueling market growth. This dynamic landscape underscores the region's commitment to innovation and healthcare advancement, positioning Europe as a key player in the global nucleic acid therapeutics CDMO market.

Market Segmentation:

Segmentation 1: by Chemical Synthesis Method

• Solid-Phase Oligonucleotide Synthesis
• Liquid-Phase Oligonucleotide Synthesis

Segmentation 2: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The Europe nucleic acid therapeutics CDMO market has been extensively segmented based on various categories, such as chemical synthesis method and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: Key players in the Europe nucleic acid therapeutics CDMO market analysed and profiled in the study involve established players that offer various kinds of nucleic acid therapeutics CDMO products.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some prominent names established in this market are:

• AGC Biologics
• BACHEM
• Eurofins Scientific
• LGC Science Group Holdings Limited
• Merck KGaA

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Market

• 1.1 Market Outlook
  • 1.1.1 Market Overview
  • 1.1.2 Product Definition
  • 1.1.3 Inclusion and Exclusion Criteria
  • 1.1.4 Key Findings
• 1.2 Industry Outlook
  • 1.2.1 Key Trends
    • 1.2.1.1 Significant Number of Collaborations among Market Players
    • 1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO Manufacturing Units
    • 1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing Environment
  • 1.2.2 Opportunity Assessment
  • 1.2.3 Patent Analysis
    • 1.2.3.1 Awaited Technological Developments
    • 1.2.3.2 Patent Filing Trend (by Country)
    • 1.2.3.3 Patent Filing Trend (by Year)
  • 1.2.4 Production Capability
  • 1.2.5 Preferred Techniques By CDMO
    • 1.2.5.1 Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
    • 1.2.5.2 Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
    • 1.2.5.3 Preferred Techniques by CDMOs for Nucleic Acid Purification
  • 1.2.6 Factors Considered While Outsourcing To CDMO.
  • 1.2.7 Regulatory Framework
• 1.3 Impact of COVID-19 on the Nucleic Acid Therapeutics CDMO
  • 1.3.1 Pre-COVID-19 Phase
  • 1.3.2 During COVID-19
  • 1.3.3 Post-COVID-19 Phase
    • 1.3.3.1 Impact on Demand and Supply
• 1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
• 1.5 Significant Usage of Nucleic Acid in Therapeutics
• 1.6 Types of Nucleic Acid Synthesized for Therapeutics
  • 1.6.1 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
  • 1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
  • 1.6.3 MicroRNAs (miRNAs)
  • 1.6.4 RNA Aptamers and RNA Decoys
  • 1.6.5 Ribozymes
  • 1.6.6 Circular RNAs
• 1.7 Business Dynamics
  • 1.7.1 Impact Analysis
  • 1.7.2 Business Drivers
    • 1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
    • 1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
    • 1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
  • 1.7.3 Business Restraints
    • 1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
    • 1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic
  • 1.7.4 Business Opportunities
    • 1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.
    • 1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented

2 Nucleic Acid Therapeutics CDMO Market (by Region)

• 2.1 Europe Nucleic Acid Therapeutics CDMO Market
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
    • 2.1.2.1 Impact Analysis
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
    • 2.1.3.2 Europe Nucleic Acid Therapeutics CDMO Market (by Country)
      • 2.1.3.2.1 Germany
        • 2.1.3.2.1.1 Germany Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.2 U.K.
        • 2.1.3.2.2.1 U.K. Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.3 France
        • 2.1.3.2.3.1 France Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.4 Spain
        • 2.1.3.2.4.1 Spain Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.5 Italy
        • 2.1.3.2.5.1 Italy Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.6 Rest-of-Europe
        • 2.1.3.2.6.1 Rest-of-Europe Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Competitive Benchmarking
  • 3.1.1 Key Strategies and Developments
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 New Offerings
    • 3.1.1.3 Mergers and Acquisitions
    • 3.1.1.4 Partnerships and Collaborations
    • 3.1.1.5 Business Expansions
    • 3.1.1.6 Regulatory and Legal Activities
  • 3.1.2 Market Share Analysis
  • 3.1.3 Visual Graphics of Key Companies
• 3.2 Company Profile
  • 3.2.1 AGC Biologics
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Role of AGC Biologics in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.1.3 Financials
    • 3.2.1.4 Recent Developments
    • 3.2.1.5 Analyst Perspective
  • 3.2.2 BACHEM
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Role of BACHEM in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.2.3 Financials
    • 3.2.2.4 Recent Developments
    • 3.2.2.5 Analyst Perspective
  • 3.2.3 Eurofins Scientific
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Role of Eurofins Scientific in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.3.3 Financials
    • 3.2.3.4 Recent Developments
    • 3.2.3.5 Analyst Perspective
  • 3.2.4 LGC Science Group Holdings Limited
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Role of LGC Science Group Holdings Limited in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.4.3 Recent Developments
    • 3.2.4.4 Analyst Perspective
  • 3.2.5 Merck KGaA
    • 3.2.5.1 Company Overview
    • 3.2.5.2 Role of Merck KGaA in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.5.3 Financials
    • 3.2.5.4 Recent Developments
    • 3.2.5.5 Analyst Perspective